Drugs / GB001
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06429566 | Jul → Dec 2023 | — | Zhejiang Echon Biopharm Limited | Unknown | No outcome recorded |
| Phase 2 | NCT03956862 | May 2019 → Jul 2020 | chronic rhinosinusitis | Gossamer Bio, Inc. | Completed | Missed primary |
| Phase 2 | NCT03683576 | Oct 2018 → Jul 2020 | asthma | Gossamer Bio, Inc. | Completed | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GB001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03683576 ↗ |
| Modality | Peptide | “recombinant peptide” NCT06429566 ↗ |
| Route | Oral | “GB001 is an oral antagonist of the prostaglandin D2 receptor” PMID 31659803 ↗ Nov 2019 |